Genetic Mutations and Family History
How do genetic mutations impact treatment? Learn why genetic testing is important for treatment and what the latest research is finding about treatments.
48 Articles
Treating Cancer By Mutation, Not by Tumor Location
Dr. Conan Kinsey outlines the latest basket trials, which focus on tumor mutation, not the location of the cancer.
RASolute 302 Trial for KRAS and Other RAS Mutations Recruiting at Multiple Sites
Dr. Hani Babiker is optimistic about the new drug to treat patients with KRAS mutations, now in a phase III trial.
Highlights from the 2025 AACR Annual Meeting
Drugs to target KRAS, better imaging for earlier detection, and cachexia prediction are among the research highlights from AACR 2025.
A Look Back at Research in 2024
Research in 2024 focused on personally tailored treatments, countering the most difficult effects of pancreatic cancer, and clinical trials.
For Families at Risk, Remote Education May Be Key in Improving Genetic Testing Uptake
What’s the best way to educate families at risk for pancreatic cancer about genetic testing? Dr. Sapna Syngal discusses the results of the GENERATE study.
ASCO GI Symposium Features a Broad Range of Pancreatic Cancer Research
Researchers at ASCO GI 2024 reported on research in health disparities, KRAS and other genetic mutations, and novel treatments.
Progress and Promise—Research in 2023
What advances were made in 2023 for pancreatic cancer treatments? Where is research headed in the coming year?
New Study Targets Specific BRAF Mutation
One type of BRAF mutation may provide a target for treatment in pancreatic cancer patients, explains Dr. Michael Pishvaian.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Progress in BRCA-Related Cancers Highlighted By the Basser Center
The Basser Center for BRCA hosted a panel discussion of the latest breakthroughs and discoveries for BRCA-related cancers.
PRECEDE Trial Sets Survival Rate Goal
Dr. Raymond Wadlow explains how earlier detection of high-risk people is key the PRECEDE trial’s goal to increase pancreatic cancer survival rates.
Putting Familial Risk In Perspective
Dr. Alison Klein works to understand the relationship between familial risk and the chances of developing pancreatic cancer.
Meet the Researcher: Nicolette Juliana Rodriguez, M.D., M.P.H.
Learn more about the research interests of Nicolette Rodriguez, M.D., M.P.H., one of the young investigators Let’s Win sponsored at AACR.
Newly Discovered Protein Complex in RAS Pathway May Provide a Treatment Target
Dr. Andrew Aguirre and other researchers from Dana-Farber and the Broad Institute are looking at the RAS pathway for a new target.
New Gene Inhibitor Drug for Patients with MTAP-Deleted Tumors
A new trial targets patients with advanced solid tumors, including pancreatic cancer, with an MTAP-deletion genetic mutation.